Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
electroCore, Inc. stock logo
ECOR
electroCore
$6.33
+3.4%
$6.20
$3.83
$8.08
$37.97M0.918,546 shs6,413 shs
IRIDEX Co. stock logo
IRIX
IRIDEX
$2.80
-1.8%
$2.83
$1.31
$3.65
$45.50M0.8234,003 shs16,348 shs
Precision Optics Co., Inc. stock logo
PEYE
Precision Optics
$1.95
$1.61
$2.69
$32.98M0.419,793 shs113,500 shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$45.12
-8.3%
$42.89
$3.56
$53.82
$1.51B-1.51476,126 shs1.60 million shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
electroCore, Inc. stock logo
ECOR
electroCore
+3.27%+9.72%-0.63%-14.59%+5.33%
IRIDEX Co. stock logo
IRIX
IRIDEX
+0.36%-2.44%-9.39%+2.56%+24.44%
Precision Optics Co., Inc. stock logo
PEYE
Precision Optics
0.00%0.00%0.00%0.00%0.00%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-8.35%+19.08%+8.05%-3.47%+1,160.34%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
electroCore, Inc. stock logo
ECOR
electroCore
0.7139 of 5 stars
0.05.00.00.02.30.80.6
IRIDEX Co. stock logo
IRIX
IRIDEX
0.0033 of 5 stars
0.02.00.00.00.60.00.6
Precision Optics Co., Inc. stock logo
PEYE
Precision Optics
N/AN/AN/AN/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.4267 of 5 stars
2.50.00.04.61.94.20.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
electroCore, Inc. stock logo
ECOR
electroCore
3.00
BuyN/AN/A
IRIDEX Co. stock logo
IRIX
IRIDEX
N/AN/A$2.00-28.57% Downside
Precision Optics Co., Inc. stock logo
PEYE
Precision Optics
N/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.00
Buy$55.6023.23% Upside

Current Analyst Ratings

Latest ECOR, SLNO, IRIX, and PEYE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/14/2024
electroCore, Inc. stock logo
ECOR
electroCore
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
2/5/2024
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$93.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
electroCore, Inc. stock logo
ECOR
electroCore
$16.03M2.37N/AN/A$1.24 per share5.10
IRIDEX Co. stock logo
IRIX
IRIDEX
$51.87M0.88N/AN/A$0.59 per share4.75
Precision Optics Co., Inc. stock logo
PEYE
Precision Optics
$15.68M0.00N/AN/A$0.53 per share0.00
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.16 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
electroCore, Inc. stock logo
ECOR
electroCore
-$18.83M-$3.56N/AN/AN/A-117.49%-201.47%-109.61%5/8/2024 (Confirmed)
IRIDEX Co. stock logo
IRIX
IRIDEX
-$9.57M-$0.59N/AN/AN/A-18.45%-75.18%-25.99%5/9/2024 (Estimated)
Precision Optics Co., Inc. stock logo
PEYE
Precision Optics
-$930K-$0.06N/AN/AN/A-5.93%-12.10%-6.41%N/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$38.99M-$2.97N/AN/AN/AN/A-79.65%-52.92%5/14/2024 (Estimated)

Latest ECOR, SLNO, IRIX, and PEYE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
electroCore, Inc. stock logo
ECOR
electroCore
-$0.50N/A+$0.50N/AN/AN/A  
3/26/2024Q4 2023
IRIDEX Co. stock logo
IRIX
IRIDEX
-$0.05-$0.18-$0.13-$0.18$14.90 million$12.46 million
3/13/2024Q4 2023
electroCore, Inc. stock logo
ECOR
electroCore
-$0.55-$0.61-$0.06-$0.61$5.23 million$5.19 million    
3/6/2024Q4 2023
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.31-$0.33-$0.02-$0.33N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
electroCore, Inc. stock logo
ECOR
electroCore
N/AN/AN/AN/AN/A
IRIDEX Co. stock logo
IRIX
IRIDEX
N/AN/AN/AN/AN/A
Precision Optics Co., Inc. stock logo
PEYE
Precision Optics
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
electroCore, Inc. stock logo
ECOR
electroCore
N/A
1.76
1.49
IRIDEX Co. stock logo
IRIX
IRIDEX
N/A
2.12
1.35
Precision Optics Co., Inc. stock logo
PEYE
Precision Optics
0.23
1.42
0.76
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/A
14.89
14.89

Ownership

Institutional Ownership

CompanyInstitutional Ownership
electroCore, Inc. stock logo
ECOR
electroCore
26.74%
IRIDEX Co. stock logo
IRIX
IRIDEX
20.10%
Precision Optics Co., Inc. stock logo
PEYE
Precision Optics
N/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%

Insider Ownership

CompanyInsider Ownership
electroCore, Inc. stock logo
ECOR
electroCore
13.14%
IRIDEX Co. stock logo
IRIX
IRIDEX
6.20%
Precision Optics Co., Inc. stock logo
PEYE
Precision Optics
22.70%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
23.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
electroCore, Inc. stock logo
ECOR
electroCore
686.00 million5.21 millionNot Optionable
IRIDEX Co. stock logo
IRIX
IRIDEX
11116.25 million15.25 millionOptionable
Precision Optics Co., Inc. stock logo
PEYE
Precision Optics
5016.92 million13.08 millionNot Optionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3333.41 million25.49 millionOptionable

ECOR, SLNO, IRIX, and PEYE Headlines

SourceHeadline
Soleno Therapeutics (NASDAQ:SLNO) Shares Gap Down to $49.23Soleno Therapeutics (NASDAQ:SLNO) Shares Gap Down to $49.23
marketbeat.com - May 3 at 9:32 PM
Vivo Opportunity, Llc Sells 750,000 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) StockVivo Opportunity, Llc Sells 750,000 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock
americanbankingnews.com - May 3 at 4:04 AM
Soleno Therapeutics Prices Public Offering Of 3 Mln Shares At $46/shr; Stock Down In After-hoursSoleno Therapeutics Prices Public Offering Of 3 Mln Shares At $46/shr; Stock Down In After-hours
nasdaq.com - May 3 at 1:48 AM
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common StockSoleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
globenewswire.com - May 2 at 10:32 PM
Soleno Therapeutics Announces Proposed Public Offering of Common StockSoleno Therapeutics Announces Proposed Public Offering of Common Stock
globenewswire.com - May 2 at 4:01 PM
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Major Shareholder Vivo Opportunity, Llc Sells 750,000 SharesSoleno Therapeutics, Inc. (NASDAQ:SLNO) Major Shareholder Vivo Opportunity, Llc Sells 750,000 Shares
insidertrades.com - May 2 at 5:48 AM
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi SyndromeSoleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
globenewswire.com - April 30 at 8:00 AM
Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide CholineSoleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline
marketwatch.com - April 29 at 4:41 PM
Soleno Therapeutics Shares Rise 37% After Breakthrough Designation for Diazoxide CholineSoleno Therapeutics Shares Rise 37% After Breakthrough Designation for Diazoxide Choline
marketwatch.com - April 29 at 4:41 PM
Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To WatchSoleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch
seekingalpha.com - April 29 at 4:41 PM
Soleno Therapeutics (NASDAQ:SLNO) Shares Gap Up to $37.89Soleno Therapeutics (NASDAQ:SLNO) Shares Gap Up to $37.89
marketbeat.com - April 29 at 12:11 PM
Why Soleno Therapeutics Stock Is Skyrocketing TodayWhy Soleno Therapeutics Stock Is Skyrocketing Today
fool.com - April 29 at 11:11 AM
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
globenewswire.com - April 29 at 8:00 AM
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - April 19 at 4:05 PM
Soleno Therapeutics (NASDAQ:SLNO) Shares Up 3.4%Soleno Therapeutics (NASDAQ:SLNO) Shares Up 3.4%
marketbeat.com - April 15 at 2:49 PM
Carlyle Group Inc. Acquires 564,242 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)Carlyle Group Inc. Acquires 564,242 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)
marketbeat.com - April 14 at 8:45 PM
Soleno Therapeutics CEO sells over $780k in company stockSoleno Therapeutics CEO sells over $780k in company stock
investing.com - April 5 at 11:15 PM
Insider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 2,218 Shares of StockInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 2,218 Shares of Stock
insidertrades.com - April 4 at 6:49 AM
Insider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO)Insider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO)
finance.yahoo.com - April 4 at 3:16 AM
CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)
finance.yahoo.com - April 4 at 3:16 AM
SLNO Apr 2024 40.000 putSLNO Apr 2024 40.000 put
finance.yahoo.com - March 16 at 10:33 PM
SLNO Apr 2024 35.000 putSLNO Apr 2024 35.000 put
finance.yahoo.com - March 16 at 7:31 AM
Construction of Solenos $22M pipe factory in Saratoga underwayConstruction of Soleno's $22M pipe factory in Saratoga underway
bizjournals.com - March 11 at 10:09 AM
Were Not Worried About Soleno Therapeutics (NASDAQ:SLNO) Cash BurnWe're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn
finance.yahoo.com - March 11 at 10:09 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

electroCore logo

electroCore

NASDAQ:ECOR
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
IRIDEX logo

IRIDEX

NASDAQ:IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Precision Optics logo

Precision Optics

OTCMKTS:PEYE
Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. It offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. The company also provides components and assemblies for industrial and military use. It markets its products to medical device companies. The company was incorporated in 1982 and is based in Gardner, Massachusetts.
Soleno Therapeutics logo

Soleno Therapeutics

NASDAQ:SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.